evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,710 questions · 14,842 findings · 1,394 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,880 · 19.4%GRADE not reported 1,413 · 9.5%Very low 3,103 · 20.9%Low 3,870 · 26.1%Moderate 2,663 · 17.9%High 913 · 6.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Tocilizumab weekly vs placebo + 52‐week taper

Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

QoL · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every 4 weeks vs placebo

Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every 4 weeks showed no clear difference in proportion of all‐cause mortality at ≥ 12 months compared with placebo (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every other week vs placebo + 52‐week taper

Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every other week vs placebo + 52‐week taper

Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every other week vs placebo + 52‐week taper

Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every other week vs placebo + 52‐week taper

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week showed no clear difference in mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review